This study evaluates the efficacy of erythropoietin in refractory autoimmune encephalitis. Ten patients will receive 100 IU/kg of erythropoietin 3 times a week for 12 weeks.
Erythropoietin can improve the refractory autoimmune encephalitis. Erythropoietin has tissue-protective effect via activation of Janus kinase (JAK)-2, signal transducer and activator of transcription (STAT)-5 pathway and NF-kappa B pathway. The activation of JAK-2 and STAT-5 promote hemoglobin synthesis and facilitate cell cycle progression. Also, NF-kappa B pathway inhibition regulates pro-inflammatory cytokine production. We expect that erythropoietin may lead to improve the symptoms and outcome of autoimmune encephalitis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
three times per a week 100IU / k
Seoul National University Hospital
Seoul, South Korea
Change from Baseline modified Rankin Scale (mRS) at 12th week
Favorable outcome is an improvement of mRS score.
Time frame: 2nd week, 12th week
Adverse effect
Common terminology criteria for adverse events (CTCAE) 4.0
Time frame: 2nd week, 4th week, 8th week, 12th week
Quality of Life in Epilepsy Inventory (QOLIE) -31
Time frame: 2nd week, 4th week, 8th week, 12th week
Mini-Mental State Examination (MMSE)
Time frame: 2nd week, 4th week, 8th week, 12th week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.